Maaike Heslinga

Maaike Heslinga

Auto-generated profile, based on publicly available information

Maaike Heslinga

Maaike Heslinga, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, The Netherlands; Department of Rheumatology, Reade, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
RAR Agca
R Agca
SHS C Heslinga
S C Heslinga
SRS Rollefstad
S Rollefstad
MHM Heslinga
M Heslinga
IMI B McInnes
I B McInnes
MNM.T. Nurmohamed
M.T. Nurmohamed
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.

11 March 2022 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
MHM Heslinga
M Heslinga
CTCharlotte E. Teunissen
Charlotte E. Teunissen
RAR Agca
R Agca
DWD van der Woude
D van der Woude
THTwj Huizinga
Twj Huizinga
MNM.T. Nurmohamed
M.T. Nurmohamed
Several biomarkers of cardiovascular function are found to be increased in rheumatoid arthritis (RA), with some suggesting a relationship with disease activity and improvement with adequate anti-rh...

15 February 2025 in The Journal of Rheumatology
Verified
Journal Article
Closed access
RHRomy Hansildaar
Romy Hansildaar
EGEva H. van Geel
Eva H. van Geel
FÇFatih Çoban
Fatih Çoban
BDBas Dijkshoorn
Bas Dijkshoorn
MHMaaike Heslinga
Maaike Heslinga
MNM.T. Nurmohamed
M.T. Nurmohamed
Objective: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular (CV) disease. Studies have suggested that treatment with apremilast is associated with weight loss and other cardiometabolic benefits. This study aimed to examine the effects of apremilast on body weight, body composition, and CV risk factors in patients with PsA.Methods: This longitudinal, nonrandomized, multicenter trial included adults with active PsA initiating apremilast (30 mg twice daily after a step-up regimen). Patients were followed for 12 months, and measurements were done at baseline and repeated at weeks 26 and 52. Body composition, the primary outcome, was assessed using dual-energy x-ray absorptiometry. Secondary outcomes included disease activity (Disease Activity Score in 28 joints [DAS28] based on C-reactive protein [CRP]), blood pressure (BP), lipids, intima-media thickness, and glucose. Statistical analysis involved mixed models adjusted for relevant covariates.Results: Forty-four patients were included, with a mean age of 56 (SD 11) years and a median BMI (kg/m2) of 28 (IQR 24-33). A total of 17 patients completed the study, whereas 27 discontinued due to ineffectiveness or side effects. After 1 year of apremilast, significant reductions were observed in multiple body mass measures, including total fat (–7.4 kg;P= 0.005) and android fat (–1.1 kg;P= 0.002). Lean mass remained stable. BP showed minor reduction, whereas lipids, intima-media thickness, and glucose levels did not change. Disease activity improved, with a significant decrease in DAS28-CRP (–0.6;P= 0.01). Android fat correlated most strongly with disease activity reduction (r0.31;P= 0.004).Conclusion: This study demonstrates that apremilast reduces fat mass in patients with PsA and suggests beneficial CV and metabolic effects, potentially reducing the risk of CV events.

1 March 2021 in Joint Bone Spine
Verified
Journal Article
Closed access
IVIngrid Visman
Ingrid Visman
MHMaaike Heslinga
Maaike Heslinga
CDChristiaan van Denderen
Christiaan van Denderen
IHIrene van der Horst-Bruinsma
Irene van der Horst-Bruinsma
AMAndreas Miltenburg
Andreas Miltenburg
MNM.T. Nurmohamed
M.T. Nurmohamed

1 June 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MHM Heslinga
M Heslinga
GLGilles Lambert
Gilles Lambert
ATA Thedrez
A Thedrez
JKJ Kastelein
J Kastelein
MNM.T. Nurmohamed
M.T. Nurmohamed
Background Patients with rheumatoid arthritis (RA) are at increased cardiovascular risk with contribution of both inflammation and traditional risk factors. Dyslipidemia is an important risk factor and lipid-lowering therapy plays a key role in cardio-preventive treatment. A new class of low density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors are now emerging. In view of a lower rate of musculoskeletal side effects these drugs might be preferred over statins in patients with RA. Active inflammation in RA leads to a decline in lipid levels, but the relation between inflammation and PCSK9 levels is unknown. Objectives To assess PSCK9 levels in RA patients, and the relationship with lipid levels and disease activity. Methods PSCK9 levels were assessed using ELISA in 97 randomly selected patients. Lipid profile assessment comprised TC, HDL-C, LDL-C and triglycerides. Disease activity was assessed using disease activity score of 28 joints (DAS28). Results The mean age of RA patients was 54.5 years (± 10.8) and they were predominantly female (74.2%). The mean PCSK9 value in RA patients was 214.75 (± 73.3), which is similar to that in the general population [1]. PCSK9 values were associated with TC (corrected B 22.34, 95% CI 6.80–37.88, p0.005) and triglycerides (corrected B 21.02, 95% CI -0.84–42.89, p0.044) (table 2). 77 patients had low disease activity (DAS28 ≤3.2), 11 patients had medium disease activity (DAS28 >3.2 and ≤5.1) and 20 patients had highly active disease (DAS28 >5.1). Mean PCSK9 values were 213.01, 246.96 and 258.30 ng/mL, respectively. Patients with active disease had a higher PCSK9 level (corrected B 42.555 95% CI 0.769–84.341, p 0.046) compared to patients with low disease activity (table 1). Relation between plasma lipids, disease activity and PCSK9 levels Conclusions PCSK9 levels in RA are similar to the general population. RA patients with active disease had higher PCSK9 levels compared to patients with low disease activity. Altogether, PCSK9 inhibitors could be an alternative treatment for dyslipidemia in RA patients who experience side effects of statins, albeit that a formal trial still has to be conducted in this category of patients. References Lambert G, Petrides F, Chatelais M et al. J Am Coll Cardiol. 2014 Jun 10;63(22):2365–73. References Disclosure of Interest None declared

1 March 2021 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MHMaaike Heslinga
Maaike Heslinga
GLGilles Lambert
Gilles Lambert
ATAurélie Thédrez
Aurélie Thédrez
JKJohn Kastelein
John Kastelein
MNMichael T Nurmohamed
Michael T Nurmohamed
Dear Editor, With interest we read the article on the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in dyslipidaemia in patients with axial spondylarthritis by de Armas-Rillo et al. [ 1]. The authors found that PCKS9 was downregulated in these patients and, in addition, observed a positive correlation between PCSK9 levels and disease activity.